<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619097</url>
  </required_header>
  <id_info>
    <org_study_id>HS-EPOP1b</org_study_id>
    <nct_id>NCT02619097</nct_id>
  </id_info>
  <brief_title>Safety &amp; Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes</brief_title>
  <official_title>Safety &amp; Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the trial are to assess the safety and pharmacokinetics profile of
      pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study started from the lowest dose, 0.08mg/kg, each group will enroll 4 to 6 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>28 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>10min before injection to 336h after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration [Tmax]</measure>
    <time_frame>10min before injection to 336h after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life [t1/2]</measure>
    <time_frame>10min before injection to 336h after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC]).</measure>
    <time_frame>10min before injection to 336h after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of hemoglobin (g/L) after treatment</measure>
    <time_frame>From date of recruitment until the date of biggest documented progression up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of reticulocyte (10^9/L) after treatment</measure>
    <time_frame>From date of recruitment until the date of biggest documented progression up to 28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>0.08mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegol-sihematide injection, 0.08mg/kg, single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegol-sihematide injection, 0.2mg/kg, single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.33mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegol-sihematide injection, 0.33mg/kg, single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegol-sihematide injection, 0.5mg/kg, single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.7mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegol-sihematide injection, 0.7mg/kg, single-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegol-sihematide injection</intervention_name>
    <description>single dose</description>
    <arm_group_label>0.08mg/kg</arm_group_label>
    <arm_group_label>0.2mg/kg</arm_group_label>
    <arm_group_label>0.33mg/kg</arm_group_label>
    <arm_group_label>0.5mg/kg</arm_group_label>
    <arm_group_label>0.7mg/kg</arm_group_label>
    <other_name>EPO-018B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women ≥18 years, premenopausal women must have negative pregnancy test.

          2. Documented diagnosis of myelodysplastic syndromes (MDS) according to World Health
             Organization (WHO) criteria, including refractory anemia (RA), refractory anemia with
             ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD),
             MDS-U, 5q-.

          3. Meets International Prognostic Scoring System (IPSS) classification of low or
             intermediate-1 risk disease as determined by microscopic and standard cytogenetic
             analysis of the bone marrow during screening.

          4. Never with erythropoietin agents treatment prior to enrollment.

          5. Eastern cooperative oncology group (ECOG) performance status of 0 or 1 during
             screening.

          6. Hemoglobin ≥7g/dL and ≤10g/dL, at least two detections during screening.

          7. Adequate transferrin saturation (≥15%), ferritin (≥12ng/mL), folate (≥ lower limits of
             normal), vitamin B12 (≥ lower limits of normal)

          8. Patients understand and are able to provide written informed consent.

        Exclusion Criteria:

          1. Pregnant or breast feeding women or women having positive pregnant test, women or men
             whose spouse plan to become pregnant with 4 weeks after the end of treatment .

          2. Therapy-related or secondary MDS.

          3. Previously diagnosed with intermediate-2 or high risk MDS per International Prognostic
             Scoring System (IPSS).

          4. History of severe allergic or anaphylactic reactions or hypersensitivity to
             erythropoiesis-stimulating agents or polyethylene glycol.

          5. History of red blood cell or blood transfusion during 4 weeks prior to enrollment.

          6. Known other disease which can lead to anemia (including haemolytic disease and
             digestive tract hemorrhage).

          7. Uncontrolled hypertension 2 weeks prior to enrollment, defined as systolic blood
             pressure ≥160mmHg or diastolic blood pressure ≥ 95mmHg.

          8. Clinically significant systemic infection or uncontrolled chronic inflammatory disease
             (ie, rheumatoid arthritis, inflammatory bowel disease) as determined by the
             investigator at screening.

          9. Evidence of bone marrow collagen fibrosis, biopsy argentaffin staining showed
             reticular fiber ≥＋＋.

         10. History of deep venous thrombosis or arterial embolism within 12 months prior to
             enrollment.

         11. History of cardiocerebrovascular events within 6 months prior to enrollment, include
             local ischemia, embolism, cerebral hemorrhage, transient ischemic attack, myocardial
             ischemia or other arterial thrombosis.

         12. Any serious medical condition, lab abnormality or psychiatric illness within 6 months
             prior to enrollment.

         13. History of malignancies other than curatively treated non-melanoma skin or in situ
             carcinoma.

         14. Estimated survival time ＜ 6 months.

         15. Plan to get major surgery which will lead to massive bleeding during the study.

         16. Treatment with any other investigational drug within 6 weeks prior to enrollment, or
             plan to participate in any other investigational drug during the study.

         17. Any other condition not specifically noted above which, in the judgement of the
             investigator, would preclude the patient from participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhijian Xiao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhijian Xiao, Doctor</last_name>
    <phone>+86-022-23909184</phone>
    <email>zjxiao@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fengkui Zhang, Doctor</last_name>
    <phone>+86-022-23909229</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijian Xiao, Doctor</last_name>
      <email>zjxiao@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhijian Xiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fengkui Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>November 29, 2015</last_update_submitted>
  <last_update_submitted_qc>November 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

